Stock Evaluator: Lakewood-Amedex Biotherapeutics, Inc. (LABT)
Lakewood-Amedex Biotherapeutics, Inc. LABT
$2.02
0.09
4.66%
July 31, 2026 4:00:00 PM
EST
Volume: 254,821
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Financial Summary
| Share Statistics | LABT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2.9 | $252.6 | 2% |
|
| Shares Out (Mil) | 0.7 | 52.3 | 3% |
|
| Institutional Ownership | 0.0% | 92.1% | 0% |
|
| Float (Mil) | 0.6 | 40.2 | 1% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 8,312 | 455 | 95% |
|
| Price Change (52-week) |
na | 52.9% | na |
|
| Growth | LABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (9.9%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($4) | ($43) | 34% |
|
| EPS (TTM) | ($8.933) | ($1.600) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($31) | 29% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $5 | $180 | 5% |
|
| Valuation | LABT | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | LABT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (834.4%) | (49.8%) | 0% |
|
| ROE | 289.4% | (55.5%) | 99% |
|
| Liabilities to Assets | na | 30.3% | na |
|
| F-Score | 1 | 3 | 1% |
|
Lakewood-Amedex Biotherapeutics, Inc. did not pass any screens on 7/31/2026.
